Tag: FALD

Mezzion Pharma’s new orphan drug udenafil improved ventricular function measured by myocardial performance index (MPI) in adolescents with congenital single ventricle heart disease (SVHD) – Further results from the pivotal 400-subject Phase 3 FUEL Trial

Coronary/Structural Heart by 0 comments

Mezzion Pharma files new patent applications to cover globally this important MPI advancement, a unique new finding as a result of treatment of SVHD patients with udenafil SEOUL, South Korea, May 18, 2020 /PRNewswire/ — Mezzion Pharma Co. Ltd. today announced that analysis of data […]

Continue Reading →